{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:30:55Z","timestamp":1785767455944,"version":"3.56.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","burnsjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Burns"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.burns.2016.01.014","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T18:30:20Z","timestamp":1454351420000},"page":"836-843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["A decade of burn unit experience with Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis: Clinical pathological diagnosis and risk factor awareness"],"prefix":"10.1016","volume":"42","author":[{"given":"Victoria M.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"DeWeese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. David","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Hom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Tuffanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Fillari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.burns.2016.01.014_bib0245","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0250","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2165\/00002018-200528100-00008","article-title":"Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors","volume":"28","author":"La Grenade","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.burns.2016.01.014_bib0255","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.1996.tb03598.x","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"135","author":"Rzany","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0260","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0265","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs, The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0270","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.burns.2016.01.014_bib0275","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis, clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: Part I, Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0285","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.burns.2013.02.009","article-title":"Acute blistering diseases on the burn ward: Beyond Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"39","author":"Richer","year":"2013","journal-title":"Burns"},{"key":"10.1016\/j.burns.2016.01.014_bib0290","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center","author":"McGee","year":"1988","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.burns.2016.01.014_bib0295","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0305-4179(00)00136-4","article-title":"Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong","volume":"27","author":"Ying","year":"2001","journal-title":"Burns"},{"key":"10.1016\/j.burns.2016.01.014_bib0300","first-page":"3","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.BCR.0000150215.78220.79","article-title":"Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center","volume":"26","author":"Haber","year":"2005","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.burns.2016.01.014_bib0310","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jaad.2011.12.014","article-title":"Toxic epidermal necrolysis: five years of treatment experience from a burn unit","volume":"67","author":"Firoz","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0315","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.burns.2013.03.011","article-title":"27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents","volume":"39","author":"Weinand","year":"2013","journal-title":"Burns"},{"key":"10.1016\/j.burns.2016.01.014_bib0320","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience","author":"Lalosevic","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0325","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0305-4179(95)00140-9","article-title":"Toxic epidermal necrolysis in a burns centre: a 6-year review","volume":"22","author":"Khoo","year":"1996","journal-title":"Burns"},{"key":"10.1016\/j.burns.2016.01.014_bib0330","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in US Burn Centers at the end of the Twentieth century","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.burns.2016.01.014_bib0335","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1468-3083.2011.04143.x","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998\u20132008","volume":"26","author":"Zajicek","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.burns.2016.01.014_bib0340","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.2147\/DDDT.S71736","article-title":"Stevens\u2013Johnson Syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of China","author":"Sun","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.burns.2016.01.014_bib0345","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0350","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2230.2010.03826.x","article-title":"Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre","volume":"35","author":"Rajaratnam","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0355","first-page":"341","article-title":"Toxic epidermal necrolysis: the experience of Coimbra's","volume":"26","author":"Pinheiro","year":"2013","journal-title":"Burn Unit"},{"key":"10.1016\/j.burns.2016.01.014_bib0360","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0365","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1346-8138.1997.tb02524.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme","volume":"24","author":"Roujeau","year":"1997","journal-title":"J Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0370","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-4632.2011.05348.x","article-title":"Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist","volume":"51","author":"Sokumbi","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0375","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archderm.1995.01690170041005","article-title":"Erythema multiforme with mucous membrane involvement and Stevens-Johnson Syndrome are clinically different disorders with distinct causes","volume":"131","author":"Assier","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0380","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0385","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"Scorten A severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0390","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/07853890701753664","article-title":"Stevens-Johnson syndrome: pathogenesis, diagnosis, and management","volume":"40","author":"Hazin","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.burns.2016.01.014_bib0395","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"A marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.burns.2016.01.014_bib0400","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.burns.2016.01.014_bib0405","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.burns.2016.01.014_bib0410","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.burns.2016.01.014_bib0415","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/11593240-000000000-00000","article-title":"Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort","volume":"13","author":"Mittmann","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0420","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jaad.2013.12.025","article-title":"HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4+ T cells","volume":"70","author":"Yang","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0425","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/archderm.1991.01680040152024","article-title":"Severe cutaneous drug reactions (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis) in human immunodeficiency virus infection","volume":"127","author":"Porteous","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00015550310002611","article-title":"Severe cutaneous reactions associated with the use of human immunodeficiency virus medications","volume":"83","author":"Rotunda","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.burns.2016.01.014_bib0435","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Gu\u00e9gan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0440","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.burns.2009.06.213","article-title":"Toxic epidermal necrolysis (Lyell's disease)","volume":"36","author":"Lissia","year":"2010","journal-title":"Burns"},{"key":"10.1016\/j.burns.2016.01.014_bib0445","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0029-7844(97)00596-6","article-title":"Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases","volume":"91","author":"Meneux","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.burns.2016.01.014_bib0450","first-page":"81","article-title":"Prevention of vulvovaginal sequelae in stevens-johnson syndrome and toxic epidermal necrolysis","volume":"4","author":"Kaser","year":"2011","journal-title":"Rev Obstet Gynecol"},{"key":"10.1016\/j.burns.2016.01.014_bib0455","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.5888\/pcd10.120123","article-title":"Neighborhood food outlets, diet, and obesity among California Adults, 2007 and 2009","volume":"10","author":"Hattori","year":"2013","journal-title":"Prev Chronic Dis"},{"key":"10.1016\/j.burns.2016.01.014_bib0460","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","article-title":"Inflammatory mechanisms in obesity","volume":"29","author":"Gregor","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.burns.2016.01.014_bib0465","first-page":"2111","article-title":"Review series inflammatory links between obesity and metabolic disease","volume":"121","author":"Lumeng","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.burns.2016.01.014_bib0470","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/ACI.0b013e3283630cc2","article-title":"Toxic epidermal necrolysis: the year in review","volume":"13","author":"Lee","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.burns.2016.01.014_bib0475","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/archdermatol.2011.239","article-title":"High-mobility Group Box 1 Protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson Syndrome","volume":"147","author":"Nakajima","year":"2015","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.burns.2016.01.014_bib0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.05.003","article-title":"Toxic epidermal necrolysis: Part II, Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"}],"container-title":["Burns"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417916000176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417916000176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T01:29:45Z","timestamp":1567560585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305417916000176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0305417916000176"],"URL":"https:\/\/doi.org\/10.1016\/j.burns.2016.01.014","relation":{},"ISSN":["0305-4179"],"issn-type":[{"value":"0305-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A decade of burn unit experience with Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis: Clinical pathological diagnosis and risk factor awareness","name":"articletitle","label":"Article Title"},{"value":"Burns","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.burns.2016.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd and ISBI. All rights reserved.","name":"copyright","label":"Copyright"}]}}